Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...